FDA Peptide Compounding Regulatory Status Continues Unchanged 46 Days After July PCAC Vote; No Proposed Rule, No Federal Register Notice
As of Tuesday September 8, 2026, the FDA has issued no proposed rule, no Federal Register notice, and no interim enforcement policy following the July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) 5-3 vote recommending six of seven candidate peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the Section 503A Bulk Drug Substances List; emideltide (DSIP) was rejected. Forty-six days have passed since the meeting ended on July 24. Center for Drug Evaluation and Research warning-letter activity to compounding pharmacies has remained elevated through Q3 2026, and no acting-FDA-commissioner statement has updated the industry timeline. The February 2027 PCAC meeting to consider cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF remains scheduled. Nominated FDA Commissioner Dr. Heidi Overton (August 19, 2026) continues to await Senate confirmation with Kyle Diamantas leading the agency in the interim. Formal FDA rulemaking to translate the PCAC recommendation into a proposed rule and then a final rule typically runs 12 to 24 months from PCAC vote; the interval of 46 days is within the normal window but longer than industry advocates had modeled at the meeting.